4D Molecular Therapeutics (NASDAQ:FDMT) reported quarterly losses of $(0.87) per share. This is a 210.71 percent decrease over losses of $(0.28) per share from the same period last year.
Several Buyers Express Interest In Crypto Lender Hodlnaut, And Its FTX Claims
Several potential buyers have signaled interest in troubled crypto lender Hodlnaut Pte, including its claims against the bankrupt crypto exchange FTX.
Hodlnaut's interim judicial managers have received multiple proposals to acquire its Singapore-based crypto business after the company sought protection from creditors.
